Eye Disease & Ophthalmology Clinical Trials Update: Week 44, 2026

Published October 30, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME)

This Phase 3 trial is testing a new injection called 4D-150 for adults with diabetic macular edema, a condition that can cause vision loss due to swelling in the retina. If the treatment proves effective, it could provide an alternative to current options like aflibercept, potentially improving vision or reducing the number of injections needed. The study is ongoing across several countries, including the US, China, and Japan, with results expected after one year.

Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia

This completed Phase 3 study tested two eye drops, LNZ100 and LNZ101, aimed at improving near vision in people with presbyopia, a common condition affecting reading and close-up tasks as people age. The treatments could offer a non-surgical way to enhance near vision without impacting distance vision. The trial enrolled 229 participants in the United States, and results are now available.

Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)

This Phase 2 trial is evaluating a gene therapy called RTx-015 for people with retinitis pigmentosa, a hereditary disease that causes vision loss over time. The treatment involves a single injection and aims to slow the progression of vision loss. The study is currently recruiting adults with this condition in the US, offering hope for a new approach to managing this rare eye disease.

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

This completed Phase 3 trial tested Nyxol eye drops to quickly reverse pupil dilation in children ages 3 to 11 after eye exams or procedures. Reversing dilation faster could mean less discomfort and quicker recovery for pediatric patients. The study included 23 participants in the US, and the results are now available.

Efgartigimod for the Treatment of Acute Optic Neuritis

This Phase 2 study is investigating efgartigimod alfa, an immunotherapy, for adults experiencing moderate to severe acute optic neuritis, an inflammation that can cause sudden vision loss. If effective, this treatment might improve vision recovery beyond what current steroid treatments offer. The trial is ongoing in the United States with follow-up visits over six months.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.